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Abstract
Background: The mortality burden of the 2009 A/H1N1 pandemic remains unclear in many countries due to delays in
reporting of death statistics. We estimate the age- and cause-specific excess mortality impact of the pandemic in France,
relative to that of other countries and past epidemic and pandemic seasons.
Methods: We applied Serfling and Poisson excess mortality approaches to model weekly age- and cause-specific mortality
rates from June 1969 through May 2010 in France. Indicators of influenza activity, time trends, and seasonal terms were
included in the models. We also reviewed the literature for country-specific estimates of 2009 pandemic excess mortality
rates to characterize geographical differences in the burden of this pandemic.
Results: The 2009 A/H1N1 pandemic was associated with 1.0 (95% Confidence Intervals (CI) 0.2–1.9) excess respiratory
deaths per 100,000 population in France, compared to rates per 100,000 of 44 (95% CI 43–45) for the A/H3N2 pandemic and
2.9 (95% CI 2.3–3.7) for average inter-pandemic seasons. The 2009 A/H1N1 pandemic had a 10.6-fold higher impact than
inter-pandemic seasons in people aged 5–24 years and 3.8-fold lower impact among people over 65 years.
Conclusions: The 2009 pandemic in France had low mortality impact in most age groups, relative to past influenza seasons,
except in school-age children and young adults. The historical A/H3N2 pandemic was associated with much larger mortality
impact than the 2009 pandemic, across all age groups and outcomes. Our 2009 pandemic excess mortality estimates for
France fall within the range of previous estimates for high-income regions. Based on the analysis of several mortality
outcomes and comparison with laboratory-confirmed 2009/H1N1 deaths, we conclude that cardio-respiratory and all-cause
mortality lack precision to accurately measure the impact of this pandemic in high-income settings and that use of more
specific mortality outcomes is important to obtain reliable age-specific estimates.
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Introduction
A novel influenza A/H1N1 virus was first isolated in April 2009
in North America and spread rapidly worldwide, leading the
World Health Organization (WHO) to declare the first influenza
pandemic of the 21st century in June 2009 [1]. Almost three years
later, the mortality impact of the 2009 A/H1N1 pandemic
remains poorly quantified in many countries, and comparisons
with the burden of previous epidemic and pandemic seasons are
scarce [2–6]. Early reports have suggested important geographical
variation in pandemic disease burden globally; however method-
ological differences hamper fair comparisons between countries
and seasons. Published mortality estimates for the 2009 pandemic
suggest a relatively low impact in Europe [2,7–9], Asia [5], and the
US [4], and a moderate impact in Mexico [6]. Overall, all
countries have consistently reported an increase of pandemic-
related deaths in younger age groups, in contrast to inter-
pandemic seasons in which 90% of deaths occur in seniors [4,6–
8,10–12].
Methodological issues in the estimation of influenza disease
burden make comparisons between countries and seasons
difficult. Laboratory confirmation of influenza-related deaths is
not conducted routinely. Although influenza testing was greatly
strengthened during the pandemic, laboratory-confirmed pan-
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demic deaths remain a gross underestimation of the overall
influenza disease burden [10]. Deaths associated with influenza
often occur following bacterial super-infection or aggravation of
chronic diseases, after primary viral infection has been cleared.
Consequently, death is often attributed to the underlying chronic
condition rather than influenza [13]. It is now well accepted that
the best approach to estimate influenza-related mortality is to
apply statistical time series seasonal regression models to different
causes of death [14–16].
Although estimates of pandemic mortality burden exist for
Europe, they are mostly limited to all-cause mortality, a non-
specific outcome, or to deaths coded specifically as influenza,
which underestimates disease burden [2,7,8]. Moreover, no study
has compared the impact of the 2009 pandemic with that of past
pandemics using a similar methodology. The objectives of our
study were to estimate the age- and cause-specific excess mortality
rates of the first wave of the A/H1N1 pandemic in France, and
compare pandemic estimates with those for seasonal epidemics
and the A/H3N2 pandemic. We also reviewed published estimates
of 2009 pandemic excess mortality rates in other countries for
comparison purposes.
Methods
Data Sources
Mortality and population data. The A/H3N2 pandemic
virus had its major impact in the 1969–70 winter in France,
similarly to other countries in Europe [17]. Hence to study the
impact of the A/H3N2 pandemic, the 2009 A/H1N1 pandemic,
and seasonal epidemics, we obtained weekly age- and cause-
specific mortality counts from June 1969 through May 2010 from
national death certificates collected by Inserm Ce´piDc [18]. We
categorized mortality based on the underlying cause of death,
using the International Classification of Disease codes for in-
fluenza, pneumonia, respiratory diseases, cardiovascular diseases,
and all causes (Text S1, Table S1). We used conversion factors
published by Ce´piDc to account for transition between classifica-
tions in France [19].
We stratified deaths by 5 different age groups (0–4, 5–24, 25–
44, 45–64, $65 yrs) and integrated yearly age-specific population
data to calculate standardized death rates [20], using the June
2009 French population structure as reference.
Viral surveillance data. Weekly percent of respiratory
specimens testing positive for influenza were obtained from the
FluNet database for France from January 1997 to June 2010,
separately for each subtype (seasonal A/H1N1, B, A/H3N2 and
pandemic A/H1N1; Figure 1) [21]. No viral surveillance data exist
before 1997 in France. Influenza virus surveillance in France relies
on a network of general practitioners [22,23] and participating
hospitals [24]. We considered an influenza subtype to be dominant
when it accounted for at least 75% of all isolates subtyped in the
respiratory season (July-June). When no single subtype accounted
for more than 75% of all isolates, we summed the contribution of
the two most prevalent subtypes.
Morbidity data. Influenza-like illness (ILI) has been shown
to be a good proxy for influenza incidence in France and
elsewhere [25,26]. Weekly ILI incidence was obtained from the
French Sentinel system, a nationwide network of general
practitioners which has been reporting electronically the weekly
number of medical visits for ILI and other infections since 1984
[27,28]. One percent of all French practitioners voluntarily
participate to disease surveillance through this system. The ILI
case definition consisted of a combination of fever .39uC,
myalgia, and respiratory symptoms. The French Sentinel Network
ILI time series have been used in a number of previous
epidemiological and modeling influenza studies aimed at detecting
outbreaks, quantifying disease burden, and characterizing the
spatio-temporal transmission dynamics of epidemics [26,29–31].
Excess Mortality Rates Estimation
Poisson model. The preferred approach to estimate in-
fluenza excess mortality is to explicitly link mortality from various
causes to indicators of influenza activity, such as ILI or viral
surveillance data [15,32]. We used Poisson regression models with
a log link [5] and considered both indicators of influenza activity
[15,32]. Models were fit to data for 1997–2010, a period when
both ILI and viral surveillance data were available. A detailed
description of the model fitting procedure is provided in Text S1
and summarized below.
First, we selected the indicator of influenza activity that
provided the best statistical fit to the mortality data. We considered
3 potential indicators: weekly ILI incidence [26], weekly influenza
virus percent positive [15], or their combination [25,33]. [We
tested various lags and moving averages of influenza indicators to
account for delays between disease onset and death (Text S1). We
selected the best influenza indicator and associated lag based on
the Akaike Information Criterion (AIC) of respiratory death
models. We focus on all-age respiratory death outcomes for this
selection procedure because respiratory mortality has intermediate
sensitivity and specificity to capture influenza mortality burden.
We also checked that the selected influenza activity indicator
maximized the correlation between observed and predicted values
of respiratory deaths.
Second, we applied Poisson models using the influenza indicator
selected by the above procedure to age- and cause-specific
mortality time series. A stepwise selection method was used to
identify the significant time trends and seasonal terms in the age-
and cause-specific models (See Text S1 for full model equation).
Baseline mortality was calculated from the Poisson model as the
expected values when influenza activity indicators are set to zero.
Excess death rates due to influenza were estimated as the
difference between predicted mortality from the full model and
baseline mortality. The seasonal number of excess deaths due to
influenza was summed for each respiratory season and age-
standardized seasonal excess mortality rates were calculated.
Confidence intervals were based on the variance of parameter
estimates (See Text S1).
Serfling model. As a sensitivity analysis, we compared excess
mortality estimates derived from the Poisson approach to those
derived from a traditional Serfling model that does not include
indicators of influenza activity, for the same time period, 1997–
2010 (details of Serfling model are provided in Text S1 and
[14,34,35]).
Given the unavailability of ILI and viral surveillance data in the
years surrounding the historical A/H3N2 pandemic, we also used
a Serfling approach to estimate the mortality impact of this
pandemic.
Results
Influenza Virus Activity, 1997–2010
The A/H3N2 subtype was dominant in 7 of the 12 inter-
pandemic seasons studied in France, 1997–2010, A/H1N1 and B
subtypes were dominant or co-dominant in 4, and there was mixed
A/H3N2-B circulation in one season. The A/H1N1 pandemic
virus was first isolated on May 1st, 2009 based on the national
influenza surveillance system [36]. Increased community trans-
mission of pandemic A/H1N1 started in September 2009, virus
Mortality Burden of the 2009 Pandemic in France
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activity peaked in the week of November 22, 2009, and A/H1N1
virus remained dominant until February 21, 2010 (Figure 1). A
sharp rise in ILI activity coincided with the pandemic period and
peaked in the last week of November 2009. Hereafter, we consider
the 2009 A/H1N1 pandemic season in France to run from May 1,
2009 to May 1, 2010.
Excess Mortality Model Selection
The best model for respiratory deaths included a 2-week lagged
moving average (t-2, t-1 and t) of ILI incidence. Based on AIC, this
model was better than models using the proportion of virus
positive or ILI multiplied by the proportion of virus positive.
A good fit was achieved for most age groups and causes of death
(Pearson correlation.0.56). Model fit was poorer for younger age
groups (especially the 0–4 yrs; Figure 2, Text S1 and Figure S1).
Model-predicted excess mortality peaks due to P&I, respiratory
and cardio-respiratory were synchronous with ILI peaks (correla-
tion between peak weeks: r.0.86, p,.0001; average lag between
peaks 2.9 weeks).
As regards the A/H1N1 pandemic season, excess P&I and
respiratory mortality rates peaked in November 2009 in all age
groups, within 1 week of the peak in ILI and viral activity. Excess
respiratory mortality increased substantially over baseline in age
groups 5–64 years during the period of peak pandemic activity.
This coincided with a small but significant increase in respiratory
mortality in people over 65 years (Figure 3).
Peaks in excess cardio-respiratory mortality coinciding with
pandemic activity were observed in age groups 5–44 yrs. In
contrast, other age groups did not experience significant excess
cardio-respiratory mortality (Figure 3, Table 1). Given the
relatively low impact of the pandemic and the young age
distribution of deaths, we concentrate below on respiratory
outcomes, and provide estimates for other outcomes as relevant.
2009–10 Pandemic Excess Mortality Estimates
All ages. We estimate that 613 excess respiratory deaths (95%
Confidence Interval (CI): 125; 1,188) were attributable to the A/
H1N1 pandemic period in France, May 2009-May 2010,
corresponding to excess death rates of 0.98 (95% CI: 0.20; 1.9)
per 100,000 population (table 1). The 2009–10 pandemic excess
mortality rate is 2.8 fold lower than those of inter-pandemic
influenza seasons. The proportion of respiratory deaths attribut-
able to influenza was 5% for the 2009–10 A/H1N1 pandemic
season, 2 times lower than for seasonal epidemics. A more specific
outcome such as P&I excess mortality suggests a similarly low
relative impact of the pandemic (Table 1). Less specific outcomes
such as cardio-respiratory and all-cause mortality provided
estimates even lower than those of respiratory outcomes, and
most of these estimates were non-significant. Sensitivity analysis
using a Serfling approach estimated that 514 (95% CI 55;
973)_excess respiratory deaths were attributable to the A/H1N1
pandemic, which is 16% lower than the estimate derived from the
Poisson approach (table 1).
Age-specific estimates. The age group 5–24 yrs was the
most severely affected by the 2009–10 A/H1N1 pandemic,
relative to the impact of seasonal epidemics (figures 2 and 3). In
this age group, A/H1N1 pandemic excess respiratory and cardio-
respiratory death rates were 10.6 to 14- fold higher than those of
seasonal epidemics and 2 to 4-fold higher than those of the most
severe A/H3N2 epidemic in 1999–2000 (table 1, table S2). In age
group 25–44 yrs, the A/H1N1 pandemic excess respiratory
mortality rate was 1.9 -fold higher than for typical influenza
seasons. In age groups 45–64 yrs, pandemic excess mortality rates
were similar to or lower than those of typical A/H3N2 seasons,
depending on the outcome.
Those over the age of 65 yrs were least affected by the A/H1N1
pandemic, relative to the impact of past seasons (Figure 3, Table 1),
with an excess respiratory death rate 3.8 fold lower than for typical
influenza seasons. The A/H1N1 pandemic estimate for cardio-
respiratory outcome was non-significant in this age group.
Respiratory estimates among children under 5 yrs were not
significant for the pandemic season, but lacked significance in
previous inter-pandemic seasons as well (table 1).
All cause excess mortality estimates were negative and non-
significant in all age groups, except for the 5–24 yrs old. A more
detailed age curve of influenza-related respiratory mortality based
Figure 1. Weekly indicators of influenza activity, France, July 1997-June 2010. The green line represents the incidence of influenza like
illnesses (ILI) per 100,000, as monitored by the French Sentinel Network. Vertical bars represent influenza virus activity, specifically the weekly percent
positive influenza virus among all respiratory specimens tested, separately for each subtype (red for 2009 pandemic influenza A/H1N1, orange for
seasonal A/H1N1-B, grey for seasonal A/H3N2).
doi:10.1371/journal.pone.0045051.g001
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on 10-yr age groups suggests that individuals under 55 yrs
experienced higher mortality rates in the A/H1N1 pandemic
than in typical influenza seasons, while older individuals experi-
enced mortality sparing (Figure 4).
In people aged 5–24 years old, the proportion of respiratory
deaths attributable to A/H1N1 pandemic influenza was unusually
high at 55%, even relative to the most severe H3N2 season in
1999–2000 (24%, P,0.03). Similarly, 28% of cardio-respiratory
mortality were attributable to the pandemic in this age group,
compared to only 7% in the most severe H3N2 season (p,0.03).
Use of a more specific outcome, such as P&I, revealed similar age
patterns, with 2.2-fold higher mortality impact during the
pandemic among those aged 5–44 yrs, relative to seasonal
epidemics, and almost 2-fold lower impact among seniors over
65 yrs (table 1).
We conducted several sensitivity analyses to test to robustness of
our estimates to the choice of the link in Poisson models (identity,
log), the definition of the pandemic period, and the choice of the
modeling approach (Poisson vs Serfling). Estimates changes by less
than 3% when using an identity link instead of a log link. Estimates
were within 2% of those in the main analysis when using a stricter
definition of the pandemic period limited to weeks when A/
H1N1pdm was predominant, Sep 2009 to Feb 2010. Finally,
sensitivity analyses using a Serfling approach confirmed the age
patterns reported in the main analysis, with excess respiratory
estimates within 0–23% of those derived from the Poisson model
(Table 1 and S2).
Comparison with the Historical A/H3N2 Pandemic
Based on the Serfling approach, we estimate that 27,600 and
42,600 excess respiratory and cardio-respiratory deaths respec-
tively were attributable to the major A/H3N2 pandemic season in
France in 1969–70 (rates of 44 and 68 deaths per 100,000
population, table 1). The proportions of deaths attributable to the
A/H3N2 pandemic were 65% and 27% respectively for re-
spiratory and cardio-respiratory mortality outcomes.
To provide a fair comparison of respiratory and cardio-
respiratory mortality burden between the A/H3N2 and the
2009–10 A/H1N1 pandemics, we considered estimates derived
from the same Serfling approach. The A/H3N2 pandemic was
Figure 2. Weekly respiratory death rates by age group, France, July 1997-June 2010. Observed death rates (black line) and predicted
death rates (blue line) by a Poisson model integrating seasonal terms, time trends and ILI data. Baseline mortality rates predicted by the Poisson
model in the absence of influenza activity are indicated by a dashed blue line. Death rates were age-standardized using the 2009 French population
as reference.
doi:10.1371/journal.pone.0045051.g002
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associated with substantially higher excess mortality impact than
the A/H1N1 pandemic across all age groups and outcomes
(Figure 4 and Table 1). Excess mortality rates were between 42
and 60-fold higher for the A/H3N2 pandemic than for the A/
H1N1 pandemic depending on the outcome.
A mortality age shift was noted in both the A/H3N2 and A/
H1N1 pandemics. While the proportions of excess respiratory
Figure 3. Weekly influenza like illnesses (ILI) overlaid with estimates of weekly numbers of influenza-related excess deaths by age
group and outcome for the pandemic and previous seasons, France, 2008–2010. The purple line represents the incidence of influenza like
illnesses (ILI) per 100,000. Red line represents excess mortality estimates for Pneumonia and influenza, green line is for respiratory mortality, and blue
for cardio-respiratory outcomes. Excess deaths are predicted by a Poisson regression model integrating influenza activity data, time trends and
seasonal terms.
doi:10.1371/journal.pone.0045051.g003
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deaths occurring in people under 65 years were 23% and 35%
during the A/H3N2 and A/H1N1 pandemics, respectively, this
age group accounted for only 7% of excess respiratory deaths
during seasonal epidemics (p,0.0001). Analysis of cardio-
respiratory outcomes suggests a similar age shift in both
pandemic seasons (22% and 23% of excess deaths in people
under 65 yrs in the A/H3N2 and A/H1N1 pandemics,
respectively, vs. 6% during seasonal epidemics).
Discussion
This is the first study to provide a systematic comparison of the
age-specific mortality burden of the 2009–10 A/H1N1 pandemic
Table 1. Excess mortality rates associated with the 2009 A/H1N1 pandemic, the historical A/H3N2 pandemic, and seasonal
epidemics by age group, death outcome, and disease burden model.
Mortality outcome
Rate per 100,000 (95% confidence interval)
Season/
Subtype Age group Pneumonia & Influenza Respiratory Cardio-respiratory All causes
Pandemic A/H1N1
2009–10, based on
Poisson model*
0–4 0.10 (0.04; 0.14) 0.02 (20.17; 0.15) 20.02 (20.30; 0.21) 20.71 (22.0; 0.5)
5–24 0.07 (0.06; 0.08) 0.13 (0.11; 0.15) 0.19 (0.14; 0.23) 0.36 (0.04; 0.67)
25–44 0.15 (0.12; 0.18) 0.19 (0.13; 0.25) 0.29 (0.10; 0.48) 0.10 (20.56; 0.75)
45–64 0.80 (0.71; 0.89) 0.78 (0.55; 1.0) 0.43 (20.31; 1.2) 20.47 (22.8; 1.8)
.65 3.5 (1.2; 5.6) 4.1 (20.94; 8.9) 23.1 (218; 11) 26.59 (241; 27)
All ages 0.86 (0.43; 1.3) 0.98 (0.04; 1.9) 20.28 (23.0; 2.4) 21.15 (27.8; 5.4)
Pandemic A/H1N1
2009–10, based on
Serfling model**
0–4 0.12 (0.02; 0.21) 0.17 (20.02; 0.36) 0.28 (20.06; 0.61) 0.74 (21.1; 2.6)
5–24 0.07 (0.04; 0.09) 0.10 (0.05; 0.15) 0.13 (0.03; 0.23) 0.39 (20.12; 0.90)
25–44 0.15 (0.10; 0.21) 0.21 (0.11; 0.31) 0.30 (0.01; 0.59) 0.74 (20.20; 1.7)
45–64 0.70 (0.54; 0.85) 0.75 (0.43; 1.1) 0.93 (0.05; 1.8) 2.7 (0.21; 5.2)
.65 1.8 (20.16; 3.7) 3.2 (21.1; 7.8) 7.4 (24.6; 19) 22 (21.9; 45)
All ages 0.54 (0.22; 0.87) 0.82 (0.09; 1.6) 1.6 (20.41; 3.6) 4.7 (0.66; 8.7)
Seasonal A/H1N1-B
based on Poisson
model
0–4 0.04 (20.06; 0.09) 0.07 (20.11; 0.21) 0.00 (20.31; 0.25) 0.48 (20.76; 1.7)
5–24 0.01 (20.02; 0.02) 0.00 (20.04; 0.03) 0.01 (20.06; 0.07) 20.12 (20.47; 0.22)
25–44 0.04 (20.01; 0.08) 0.07 (20.01; 0.13) 0.33 (0.13; 0.53) 20.20 (20.86; 0.45)
45–64 20.02 (20.15; 0.10) 0.14 (20.12; 0.39) 1.01 (0.25; 1.8) 2.3 (20.02; 4.6)
.65 20.90 (23.9; 1.9) 1.02 (24;9; 6.6) 8.2 (27.1; 23) 13 (221; 46)
All ages 20.14 (20.70; 0.37) 0.23 (20.86; 1.3) 1.7 (21.1; 4.5) 2.7 (24.0; 9.2)
Seasonal A/H3N2
based on Poisson
model*
0–4 0.03 (20.09; 0.08) 0.05 (20.12; 0.18) 20.03 (20.30; 0.19) 0.23 (20.82; 1.2)
5–24 0.04 (0.02; 0.05) 0.02 (20.01; 0.05) 0.02 (20.04; 0.07) 0.10 (20.19; 0.37)
25–44 0.10 (0.06; 0.12) 0.14 (0.08; 0.19) 0.30 (0.14; 0.46) 0.49 (20.06; 1.0)
45–64 0.42 (0.33; 0.50) 0.99 (0.79; 1.2) 2.0 (1.4; 2.6) 5.2 (3.3; 7.1)
.65 15 (13.4; 17) 30 (25.9; 34) 65 (53; 76) 105 (78; 132)
All ages 2.7 (2.4; 3.1) 5.4 (4.6; 6.1) 11 (9.2; 14) 19 (13.9; 24)
Pandemic A/H3N2
1969–70 based on
Serfling model**
0–4 4.2 (3.9; 4.5) 5.5 (5.0; 6.1) 6.7 (6.0; 7.4) 9.0 (5.7; 12)
5–24 0.73 (0.69; 0.77) 0.92 (0.84; 0.99) 1.1 (0.93; 1.2) 1.4 (0.40; 2.5)
25–44 3.1 (3.1; 3.2) 4.4 (4.3; 4.6) 6.2 (5.7; 6.6) 9.6 (8.3; 11.0)
45–64 21 (21; 22) 32.1 (31.5; 32.7) 50 (48; 52) 74 (70; 78)
.65 152 (150; 155) 203 (197; 209) 316 (294; 339) 424 (386; 462)
All ages 32 (32; 33) 44 (43; 45) 68 (64; 72) 94 (87; 100)
*Estimates are based on a Poisson regression model linking weekly mortality with weekly incidence of influenza like illness (average based on 4 A/H1N1–B epidemics
and based on 7 A/H3N2 epidemics for seasonal epidemics).
**Estimates based on the traditional Serfling seasonal regression approach, which does not incorporate indicators of influenza activity.
doi:10.1371/journal.pone.0045051.t001
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with the historical A/H3N2 pandemic, based on detailed
comparison of mortality outcomes and modeling approaches.
Our burden estimates are based on a rigorous model selection
approach considering several indicators of influenza activity. We
estimate that the first season of circulation of the novel A/H1N1
pandemic virus in France (May 2009-May 2010) was associated
with 0.98 excess respiratory deaths (95% CI: 0.20; 1.9) per
100,000. Relative to seasonal influenza, individuals aged 5–24 yrs
were the most severely affected by the pandemic and experienced
excess respiratory death rates 10.6 fold higher than those of
seasonal epidemics. In contrast, the pandemic mortality burden in
seniors over 65 years old was 3.8 fold lower than that of typical
inter-pandemic seasons. The 2009–10 A/H1N1 pandemic was
substantially milder than the A/H3N2 pandemic in France,
consistently across all age groups and mortality indicators.
The French authorities identified 264 laboratory-confirmed
pandemic A/H1N1 influenza deaths between July 1st, 2009 and
February 28, 2010 [37] and 349 deaths listing an influenza code
on the death certificate [36]. Our relatively conservative estimate
of 613 pandemic excess respiratory deaths suggests that nearly 1 in
2 influenza-related deaths was laboratory confirmed, in a period
where testing was considerably strengthened. For comparison
purpose, a Mexican study suggested that only 1 in 7 influenza-
related deaths were captured in laboratory-confirmed surveillance
[6]. In France, the proportion of deaths occurring among seniors
over 65 yrs was 26% based on laboratory-confirmed deaths [37],
44% based on deaths specifically coded as influenza [36] and 68%
based on excess mortality models. The age distribution difference
could be explained by a lesser propensity to confirm and diagnose
influenza-related deaths among seniors than among younger
individuals, as was reported for Mexico [6]. Alternatively, we
could have overestimated excess respiratory death rates in seniors.
However, a rise in P&I and respiratory mortality in this age group
coincided with a period of intense pandemic activity in November-
December 2009, lending validity to our estimates. In addition, we
obtained a similar age distribution of influenza-related pandemic
deaths by the Serfling approach (65% of excess respiratory deaths
among seniors).
Overall, the mortality burden of the 2009–10 A/H1N1
pandemic in France was particularly mild, relative to the impact
of seasonal influenza, except in the 5–44 yrs age group. Older
populations did not experience significant excess cardio-respirato-
ry and all cause mortality coinciding with the period of intense
pandemic A/H1N1 activity. Most remarkably, the only age group
to experience significant all-cause excess mortality rates was the 5–
24 yrs, while all-cause estimates were negative in all other age
groups, consistent with mortality patterns in other European
countries [8,38]. We therefore consider that P&I and respiratory
deaths are the most reliable outcomes to model the age-specific
mortality burden of the A/H1N1 pandemic in Europe and note
that previously published all-cause mortality estimates from high-
income countries in North America, Europe, and Asia may lack
precision [4–6,8,9].
Our data confirm that the main waves of the A/H3N2 and A/
H1N1 pandemics in France were characterized by mortality age
shifts, with a significant increase in the proportion of excess
respiratory deaths among people under 65 years during pan-
demics, relative to inter-pandemic seasons. Our results and those
of others reinforce one of the signature features of influenza
pandemics – a younger than usual age distribution of influenza-
Figure 4. Age-specific excess death rates associated with the 2009–10 A/H1N1 pandemic, the 1969–70 A/H3N2 pandemic and
seasonal A/H3N2 and A/H1N1-B epidemics, for different mortality outcomes. Excess mortality rates are estimated by a Serfling seasonal
regression model, P&I: Pneumonia and influenza.
doi:10.1371/journal.pone.0045051.g004
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related deaths [11,39–41]. In pandemic situations, a more
appropriate estimation of disease burden may be the years of life
lost approach, which integrates the age distribution of deaths with
excess mortality estimates [42]. We applied the years of life lost
approach to French data, revealing a 2–2.6 fold higher impact for
the 2009 pandemic than for seasonal epidemics in people under
45 yrs, corroborating findings from other settings (table 2, [4,6]).
There are several limitations to our study. First, we developed
a Poisson regression model linking mortality with influenza activity
data, which is a more specific approach to estimate influenza-
related mortality than the traditional Serfling method [16].
However, this approach may be less widely applicable than the
Serfling method in that it requires several years of reliable weekly
viral activity data collected with systematic surveillance criteria,
which is not always the case in pandemic situations [16]. Also, we
obtained negative 2009–10 pandemic estimates for less specific
outcomes in individuals over 45 yrs by the Poisson approach,
while the Serfling method gave positive estimates, in particular for
cardio-respiratory deaths. Another caveat relates to the use of ILI
as a proxy of influenza activity in Poisson models. Sensitivity
analyses identified ILI as the best covariate to model respiratory
deaths, over any indicator relying on influenza virus surveillance
data. The poorer statistical fit of models incorporating the
influenza virus surveillance data, even after standardization,
smoothing, and allowing for lags, could be related to age biases
in influenza testing or lack of information on circulation of other
respiratory viruses. Specifically, if the majority of virus specimens
were collected from children, weekly viral surveillance activity
could be asynchronous with weekly senior mortality rates and
decrease model fit. Our models driven by ILI, which were selected
based on statistical grounds, may not be the most biologically
relevant in that they may include the contribution of various
pathogens and overestimate the contribution of influenza.
However, ILI data do not introduce an age bias if all age groups
are represented and the probability of influenza infection given ILI
is similar across age groups [43]. Most importantly, models driven
by viral activity data suggest a similar pandemic mortality burden
as models driven by ILI, with an excess mortality rate estimated at
0.93 per 100,000.
A third limitation relates to the fact that we did not include
weekly indicators of respiratory syncytial virus (RSV) activity and
other pathogens proxies in our models. Lack of RSV information
could explain why our mortality estimates for seasonal influenza
lack significance in children under 4 years, an age group where
RSV predominates [15]. RSV-coded deaths were concentrated in
January-March 2010 in France, suggesting that RSV activity did
not overlap with the period of intense pandemic A/H1N1 virus
activity in late fall. It is possible however that RSV circulation was
displaced by pandemic activity [44], potentially affecting our
estimate of baseline mortality in younger age groups. Similarly, the
contribution of other seasonal factors such Streptococcus Pneu-
moniae and cold spells would be more important in winter, several
weeks and months after pandemic activity had peaked [45].
Overall, many countries lack age-specific information on various
respiratory pathogen activity; such data will be useful to improve
excess mortality models in the future [46].
A final caveat of our study is the lack of adjustment on time
trends in health care and treatment, which matter for comparison
of mortality rates associated with recent and historical pandemics.
During the historical A/H3N2 pandemic, pediatric intensive care
units did not exist in some countries and some of the children who
survived in 2009 would have probably succumbed during the
earlier pandemic. Treatment of secondary bacterial infections [47]
and complications has greatly improved since the 1960 s, together
with widespread use of antivirals in the community and hospital
settings, and occasional use of extracorporeal membrane oxygen-
ation. Although our analyses did not adjust for these factors, the
order of magnitude difference between mortality estimates for the
two pandemics suggests factors that go beyond healthcare and
treatment. The substantial severity of the A/H3N2 pandemic in
France, relative to the 2009 A/H1N1 pandemic, could be
explained by differences in virus virulence or prior immunity.
The burden of the 2009 pandemic was likely mitigated by
substantial cross protective immunity with previously circulating
A/H1N1 viruses [6–10,48,49] and/or cross-subtypic immunity
from previous exposure to A/H3N2. By contrast, immunity from
vaccination was minimal in the first wave of the 2009 pandemic in
most countries due to delays in vaccine production and delivery.
Table 2. Year of Life Lost associated with the 2009–10 A/H1N1 pandemic, the 1969–70 A/H3N2 pandemic, and seasonal
epidemics, by mortality outcome.
Standardized Rate per 100,000 (95% Confidence intervals)
P&I Respiratory Cardio-respiratory
All age
A/H1N1 2009–10 17 (11; 23) 19 (8; 33) 10 (3; 44)
Seasonal A/H1N1-B** 3 (1; 7) 8 (2; 20) 36 (9; 72)
Seasonal A/H3N2* 38 (32; 43) 74 (62; 86) 157 (125; 190)
A/H3N2 1969–70 559 (549; 569) 774 (752; 796) 1180 (1106; 1255)
Among persons under 45 years
A/H1N1 2009–10 6 (4; 7) 8 (6; 11) 12 (6; 19)
Seasonal A/H1N1-B** 2 (1; 3) 3 (1; 6) 9 (3; 16)
Seasonal A/H3N2* 4 (2; 5) 4 (2; 7) 8 (3; 14)
A/H3N2 1969–70 125 (120; 130) 171 (161; 180) 222 (203; 242)
Estimates are given as rates per 100,000 population.
*based on 4 A/H1N1–B seasonal epidemics.
**based on 7 A/H3N2 seasonal epidemics.
P&I: Pneumonia and Influenza.
doi:10.1371/journal.pone.0045051.t002
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Pandemic vaccination was initiated on November 2nd 2009 in
France, just 3 weeks before peak viral activity, and only 7.9% of
the population was vaccinated by February 2010 [50].
Important between-country variation in the mortality burden of
historical pandemics has been reported [17,51]. Our study reveals
the particularly high excess mortality impact of the A/H3N2
pandemic in France, relative to more recent epidemic or
pandemic seasons. Previous work has highlighted the severity of
the A/H3N2 pandemic in Western Europe, as compared with the
Americas [17,52]. To gauge geographical variation in 2009
pandemic mortality burden, we reviewed published national
studies providing age-specific mortality estimates for the 2009–
10 A/H1N1 season (Table 3). Despite between-country variations
in absolute estimates, most countries reported lower all-age excess
mortality burden for the 2009 pandemic than for recent seasonal
epidemics. School-age children and young adults experienced
atypical mortality increase in most countries, including the UK,
US and Mexico [6,8,10,38,53], consistent with our data. Similar
results were found by pooling all-cause mortality data from eight
European countries or regions [53]. In contrast to other European
studies, the Netherlands reported unusually high pandemic burden
in children under 4 yrs [9]. All countries reported lower than
expected mortality burden among seniors, with a ratio of
pandemic to epidemic excess mortality rates ranging from 0.16–
0.34 across 6 countries on 3 continents. We note however that of
the 7 studies providing excess mortality estimates based on vital
statistics [6,8,10,38,53], 5 studies focus on all-cause mortality. This
is unfortunate because our study suggests that all-cause mortality
may not provide the most precise estimates of 2009 pandemic
burden, especially in Europe where the pandemic was particularly
mild. Moreover, not all studies provide 95% confidence limits on
the estimates, and methodologies differ between studies. Finally,
little information on the mortality burden of past and recent
pandemics is available from low-income countries of Asia and
Africa, which is a key area for future research.
Our study adds to the growing body of evidence on the burden
of the 2009 A/H1N1 pandemic and suggests a relatively low
excess mortality impact in France compared to seasonal influenza,
except in school-age children and young adults. Our results
suggest that it is important to analyze cause-specific mortality
outcomes, such as respiratory deaths, to accurately capture the
burden of influenza in mild seasons, such as the 2009 pandemic.
All-cause mortality models provided negative estimates for the
pandemic in France, which is clearly imprecise as at least 264
laboratory-confirmed deaths are directly attributable to pandemic
influenza A/H1N1. Estimates from many more settings, including
low and middle income countries, are needed before the full
spectrum of geographical variation in pandemic mortality burden
can be established and the socio-economic and population
determinants of disease burden are fully elucidated.
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